Sechenov Medical Journal

Advanced search


Full Text:


The review presents new pharmaceuticals for the treatment of anemia in chronic kidney disease that have been developed in recent years and are currently in the clinical testing phase. Mechanisms of action, as well as potential side effects are examined. Based on the analysis of data from preliminary clinical trials, it is concluded that the new pharmaceuticals are highly effective and well tolerated by patients, and in the coming years, could be included in the therapeutic arsenal for treatment of nephrogenic anemia.

About the Authors

K. A. Aitbaev
National Center of Cardiology and Therapy named after Academician Mirsaid Mirrahimov
Russian Federation

I. T. Murkamilov
National Center of Cardiology and Therapy named after Academician Mirsaid Mirrahimov
Russian Federation

V. V. Fomin
I.M. Sechenov First Moscow State Medical University
Russian Federation


1. Winearls C.G., Oliver D.O., Pippard M.J. et al. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis // Lancet. 1986; 2:1175-1178.

2. Besarab A., Amin N., Ahsan M. et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients // J. Am. Soc. Nephrol. 2000;11:530-538.

3. Livnah O., Stura, E. A., Middleton S. A. et al. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation // Science. 1999; 283:987-990.

4. Koury M. J. Erythropoietin: the story of hypoxia and a finely regulated hematopoietic hormone // Exp. Hematol. 2005; 33:1263-1270.

5. Дворецкий Л.И., Желнов И.В., Дятлов И.В. Клиническое значение анемии у больных сердечной недостаточностью // Сеченовский вестник. 2010;2:22-27.

6. Fishbane S., Schiller B., Locatelli F. et al. EMERALD Study Groups. Peginesatide inpatients with anemia undergoing hemodialysis // N. Eng. J. Med. 2013; 368:307-319.

7. Macdougall I.C., Provenzano R., Sharma A. et al. PEARL Study Groups. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis // N. Engl. J. Med. 2013; 368:320-332.

8. López-Gómez J.M., Jofre R., Moreno F. rHuEpo before dialysis and in dialysed patients // Nephrol. Dial. Transplant. 1995; 10 Suppl. 6:31-35.

9. López-Gómez J.M., Gonzalez C., Lu ˜ no J. et al. Asociación entre hepatopatía y mejoría de laanemia en pacientes en hemodiálisis periódica // Nefrología.1981; 2:35-38.

10. Verdalles U., Abad S., Vega A. et al. Factors related to the absence of anemia in hemodialysis patients // Blood Purif. 2011; 32:69-74.

11. Blumberg A., Keller H., Marti H.R. Effect of altitude on erythropoiesis and oxygen affinity in anaemic patients on maintenance dialysis // Eur. J.Clin. Invest. 1973:3:2:93-97.

12. Maxwell P.H., Eckardt K.U. HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond // Nat.Rev.Nephrol. 2016; 12:157-168. doi:10.1038/nrneph.2015.193

13. Scortegagna M., Morris M. A., Oktay Y. et al. Bennett M., Garcia J. A. The HIF family member EPAS1/HIF-2α is required for normal hematopoiesis in mice // Blood 2003; 102:1634-1640.

14. Gruber M., Hu C. J., Johnson R. S. et al. Acute postnatal ablation of Hif-2 alpha results in anemia // Proc. Natl. Acad. Sci. USA 2007; 104:2301-2306.

15. Kapitsinou P. P., Liu Q., Unger T. L. et al. Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia // Blood. 2010; 116:3039-3048.

16. Rhodes M. M., Kopsombut P., Bondurant M. C. Bcl-xL prevents apoptosis of late-stage erythroblasts but does not mediate the antiapoptotic effect of erythropoietin // Blood. 2005; 106:1857-1863.

17. Simonson T. S., McClain D. A., Jorde L. B. et al. Genetic determinants of Tibetan high-altitude adaptation // Hum. Genet. 2012; 131:527-533.

18. Penaloza D., Arias-Stella J. The heart and pulmonary circulation at high altitudes: healthy highlanders and chronic mountain sickness // Circulation. 2007; 115: 1132-1146.

19. Wenger R. H., Stiehl D. P., Camenisch G. Integration of oxygen signaling at the consensus HRE // Sci. STKE 2005;306:18:re12.

20. Semenza G. L. HIF-1 and mechanisms of hypoxia sensing // Curr.Opin. Cell Biol. 2001; 13: 167-171.

21. Morita M., Ohneda O., Yamashita T. et al. HLF/HIF-2αis a key factor in retinopathy of prematurity in association with erythropoietin // EMBO J. 2003; 22:1134-1146.

22. Scortegagna M., Ding, K., Zhang, Q. et al. HIF-2αregulates murine hematopoietic development in an erythropoietin-dependent manner. Blood. 2005; 105:3133-3140.

23. Mastrogiannaki M., Matak P., Keith B. et al. HIF-2α, but not HIF-1α, promotes iron absorption in mice // J.Clin. Invest. 2009; 119:1159-1166.

24. Percy M. J., Furlow P. W., Lucas G. S. et al. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis // N. Engl. J. Med. 2008; 358:162-168.

25. Umetani M., Nakao H., Doi T. et al. A novel cell adhesion inhibitor, K-7174, reduces the endothelial VCAM-1 induction by inflammatory cytokines, acting through the regulation of GATA // Biochem.Biophys.Res.Commun.2000; 272;2:370-374.

26. Nakano Y., Imagawa S., Matsumoto K. et al. Oral administration of K-11706 inhibits GATA binding activity, enhances hypoxia-inducible factor 1 binding activity, and restores indicators in an in vivo mouse model of anemia of chronic disease // Blood. 2004; 104:4300-4307.

27. Schwoebel F., van Eijk L.T., Zboralski D. et al. The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys // Blood. 2013;121:2311-2315.

28. Van Eijk L.T., John A.S., Schwoebel F. et al. Effect of the antihepcidin spiegelmerlexaptepid on inflammation-induced decrease in serum iron in humans // Blood. 2014;124:2643-2646.

29. Ruckle J., Jacobs M., Kramer W. et al. Single-dose, randomized double-blind,placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women // J Bone Miner. Res. 2009; 24:744-752.


Views: 201

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2218-7332 (Print)
ISSN 2658-3348 (Online)